|
|||||
|
|
| 重组人P53腺病毒注射液联合化疗治疗晚期恶性肿瘤的近期疗效评价 | |
| 引用本文： | 陈锐,;仝晓敬,;马跃,;陶亚楠,;王治海. 重组人P53腺病毒注射液联合化疗治疗晚期恶性肿瘤的近期疗效评价[J]. 临床和实验医学杂志, 2014, 0(16): 1326-1329 |
| 作者姓名： | 陈锐, 仝晓敬, 马跃, 陶亚楠, 王治海 |
| 作者单位： | [1]首都医科大学附属北京同仁医院检验科,北京 100730; [2]首都医科大学临床流行病学北京市重点实验室,北京 100069 |
| 基金项目： | 首都医科大学重点实验室开放课题（编号2013LCLB03）;首都医科大学2013年度本科生科研创新项目（编号xsky2013099） |
| 摘 要： | 目的探讨重组人P53腺病毒注射液联合化疗治疗晚期恶性肿瘤的近期临床疗效。方法收集晚期恶性肿瘤患者70例,采用重组人P53腺病毒注射液联合化疗方案治疗,评估患者的近期疗效及治疗前后肿瘤标志物癌胚抗原(CEA)、癌抗原199(CA199)和癌抗原153(CA153)水平。结果本组治疗有效率为55.7%,控制率为88.6%;治疗后鼻咽癌、胰腺癌、非小细胞肺癌和消化道癌的CEA水平均显著降低(P0.05);胰腺癌和消化道癌患者的CA199水平显著降低(P0.05),而鼻咽癌和非小细胞肺癌CA199水平无显著变化(P0.05);消化道癌CA153水平显著降低(P0.05);而鼻咽癌、胰腺癌和非小细胞肺癌患者CA153水平无显著变化(P0.05)。不良反应主要为化疗副性反应。结论重组人P53腺病毒注射液联合化疗治疗晚期恶性肿瘤具有显著近期疗效,能够改善患者的生存质量,毒副作用轻,值得推广应用。 |
| 关 键 词： | 晚期恶性肿瘤 重组人P53腺病毒化疗 肿瘤标志物 |
The recent clinical efficacy of recombinant human Ad-P53 agent -gendicine combined chemotherapy in malignant tumor patients |
|
| Affiliation: | CHEN Rui, TONG Xiao -jing , MA Yue , et al.( 1 Department of Clinical Laboratory, Beijing Tongren Hospital Affiliated to Capital Medical U- niversity, Beifing 100730, China ; 2 Department of Epidemiology and Health Statistics, School of Public Health and Family Medicine, Capital Medi- cal University, Beijing 100069, China.) |
| Abstract: | Objective To investigate the effect of recombinant human P53 adenovirus injection（Gendicine）recent clinical curative effect of combined chemotherapy in the treatment of advanced malignant tumor. Methods 70 patients with advanced malignant tumor treated in our hospital used Gendicine combined chemotherapy in the treatment of patients. The treatment efficacy was evaluated. Results The effective rate of the treatment group was 55. 7%,control rate was 88. 6%. After the treatment of nasopharyngeal carcinoma,pancreatic cancer,NSCLC and gastrointestinal cancer,CEA tumor markers are significantly different from pre - therapy（ P ﹤0. 05）. In patients with pancreatic cancer and gastrointestinal cancer,tumor markers CA199 had significant difference（ P ﹤0. 05）. No obvious changes of CA199 in nasopharyngeal carcinoma and NSCLC group were found（ P ﹥0. 05）. The level of CA153 in gastrointestinal cancer,tumor marker showed significant different level（ P ﹤ 0. 05）. In gastrointestinal cancer pancreatic cancer and NSCLC,changes of CA153 is not significan（t P ﹥0. 05）. The main adverse reactions is caused by chemotherapy. Conclusion Gendicine combined with chemotherapy in treatment of advanced malignant tumor has significant curative effect. This treatment method can improve the patient＆#39;s quality of life. Side effects are not severely. It is worthy of popularization and application. |
| Keywords: | Advanced malignancies Recombinant adenovirus - P53 Chemotherapy Tumor markers |
| 本文献已被 CNKI 维普 等数据库收录！ | |